Octrea

Octrea

octreotide

Manufacturer:

Apexcela

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Octreotide acetate
Indications/Uses
Symptomatic control & reduction growth hormone (GH) & IGF-1 plasma level in patient w/ acromegaly who are inadequately controlled by surgery or RT. Acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radioactive becomes fully effective. Symptomatic relief associated w/ functional gastro-entero-pancreatic (GEP) endocrine tumors eg, metastatic carcinoid tumors, profuse watery diarrhea associated w/ VIP-secreting tumors; gastrinoma (Zollinger-Ellison syndrome) in combination w/ PPIs; pre-op control of hypoglycemia & for maintenance therapy. Prevention of complications following pancreatic surgery, emergency management to stop bleeding gastroesophageal varices in patients w/ cirrhosis, endoscopic sclerotherapy; HIV-associated diarrhea, pancreatic endocrine tumors (especially islet cell tumors).
Dosage/Direction for Use
SC Adult Symptoms associated w/ carcinoid tumors w/ features of carcinoid syndrome, VIPomas, glucagonomas, gastro-entero-pancreatic endocrine tumors Initially 50 mcg (0.05 mg) once daily to bid adjusted based on response. May be increased to 200 mcg tid. Discontinue after 1 wk if no effect in carcinoid tumors. Acromegaly, short term treatment before pituitary surgery or long-term treatment in those inadequately controlled by other treatment or by RT or until RT become fully effective 100-200 mcg tid. Discontinue if no response w/in 3 mth. Prevention of complication following pancreatic surgery 100 mcg tid for 7 consecutive days starting on the day of operation at least 1 hr prior to laparotomy. HIV-associated diarrhea Initially 100 mcg tid, may be titrated to 250 mcg tid if diarrhoea is not controlled after 1 wk. IV infusion Bleeding gastro-esophageal varices 25 mcg/hr for 5 days by continuous IV infusion. Cirrhotic patients w/ bleeding gastro-esophageal varices Up to 50 mcg/hr for 5 days.
Contraindications
Special Precautions
Monitor thyroid function (TSH, total &/or free thyroxine) in patients receiving long-term therapy; monitor vit B12 levels during therapy in patients who have history of vit B12 deprivation. CV related events. Perform ultrasonic exam of gallbladder before, & at about 6-12 mth intervals during therapy; cholelithiasis may occur. Gastroenterohepatic endocrine tumors. Observe closely for symptomatic evidence of hypoglycemia or hyperglycemia whenever therapy is initiated. Increased risk for the development of insulin-dependent diabetes or changes in insulin requirement in patients w/ preexisting diabetes; monitor blood glucose levels.  Liver & renal function impairment. Pregnancy & lactation. Childn <18 yr. Elderly >65 yr.
Adverse Reactions
Diarrhea, loose stools, abdominal discomfort, bloating, constipation, nausea, vomiting; bruising, hair loss, pruritus; fatigue, headache, malaise, dizziness; flu-like symptoms, pollakiuria, visual disturbance.
Drug Interactions
β-blockers, Ca channel blockers, or agents to control fluid & electrolyte balance, cyclosporine, cimetidine, insulin & antidiabetics, bromocriptine. Drugs w/ low therapeutic index eg, quinidine, terfenadine.
MIMS Class
Other Gastrointestinal Drugs / Trophic Hormones & Related Synthetic Drugs
ATC Classification
H01CB02 - octreotide ; Belongs to the class of antigrowth hormone. Used in hypothalamic hormone preparations.
Presentation/Packing
Form
Octrea soln for inj 100 mcg/mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in